Advanced Oncotherapy: LIGHT – regulatory update

Hardman & Co
[shareaholic app="share_buttons" id_name="post_below_content"]

Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex assembly of its first full energy system, optimising, validating and verifying all aspects of this process. Meanwhile, it is liaising with the relevant regulators as part of the approval process. The FDA has requested some specific beam measurement data, which has added three months to the process but will generate important technical data that differentiates LIGHT and could be used in future marketing.

  • Strategy: Advanced Oncotherapy is developing a compact and modular PT system, which is affordable for the payor, financially attractive to the operator, and generating superior patient outcomes. AVO benefits from technology know-how developed by ADAM (CERN spin-off), and relies on a world-class supplier base.
  • Regulatory update: Although the FDA has requested some specific proton beam measurement data that will add up to a maximum of three months to the completion schedule, it highlights the progress that AVO has made with the FDA, and US regulatory approval now appears likely to come ahead of CE marking.
  • First LIGHT: Having been developing this highly technical and complex project for the past six years, the FDA’s request for additional data suggests that the first fully energy LIGHT system will now be completed by the end of 2Q’22. However, the market should be comforted by the progress made towards US approval.
  • Risks: To date, one of the key risks has been funding. However, AVO’s recent largest capital increase, coupled with alternative financing arrangements, have greatly diminished this risk. Regulatory risks have been reduced through ongoing dialogue with the FDA via the modular Q-Submission 510(k) process.
  • Investment summary: After some years in development Advanced Oncotherapy is nearing the finishing line with its first LIGHT system. However, the goal is to have a pipeline of installations to satisfy the pent-up demand and bring down the cost of PT. The current EV is lower than the quantum of investment to get LIGHT to where it is today. Additionally, the NPV of the cashflows from all potential sources of income from AVO’s evolving business model is currently 215p (161p fully diluted).

DOWNLOAD THE FULL REPORT

Share on:
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Chesnara plc 20 Years of Dividend Growth Backed by £1.5 Billion Acquisition Surge (Video)

    Dr Brian Moretta explains how disciplined deal-making, strong cash generation, and operational progress across the UK and Europe are reinforcing Chesnara’s position

    Arbuthnot Banking Group: Franchise Growth and 2025 Outlook (LON:ARBB)

    Discover how Arbuthnot Banking Group is thriving despite market challenges, with significant growth in specialist lending and wealth management in 2024.

    Apax Global Alpha: Stronger prospects for 2025 and beyond (LON:APAX)

    In a recent interview, Mark Thomas from Hardman & Co discusses Apax Global Alpha's (LON:APAX) recent performance, future growth, and investment strategies.

    Arbuthnot Banking Group Profits Dip but Franchise Growth Signals a Strategic Masterstroke (Video)

    Analyst Mark Thomas of Hardman & Co breaks down how the Group is building long-term shareholder value by expanding specialist lending, attracting new banking clients, and scaling its wealth management business.

    NB Private Equity Partners: NAV Update, Capital Strategy & Market Outlook

    Discover insights from analyst Mark Thomas on NB Private Equity Partners plc (LON:NBPE) as he discusses key trends, capital allocation, and market dynamics.

      Search

      Search